This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, and 10-year disease incidence and prevalence forecasts, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2021, there were 422,000 incident cases of uterine cancer in females worldwide, and expects that number to increase to 440,000 incident cases by 2030.
• In the same year, there were an estimated 1.43 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.48 million cases by 2030.
• GSK’s Jemperli, Merck & Co’s Keytruda, and Eisai’s Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes.
• The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in Phase III.
• Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
• High-impact upcoming events for drugs in the uterine cancer space comprise topline Phase III trial results for Jemperli and Xpovio.
• The overall likelihood of approval of a Phase I solid tumors asset is 5.1%, and the average probability a drug advances from Phase III is 41.4%. Drugs, on average, take 9.9 years from Phase I to approval in the solid tumors space, as well as in the overall oncology space.
• The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 98% of trials in Phase I–II, and only 2% in Phase IV.
• The US has a substantial lead in the number of uterine neoplasms clinical trials globally. Spain leads the major European markets, while South Korea has the top spot in Asia.
• Clinical trial activity in the uterine neoplasms space is dominated by completed trials. AstraZeneca and Sanofi have the highest number of completed clinical trials for uterine neoplasms, with five trials each.
• AstraZeneca, Merck & Co, and Sanofi lead the industry sponsors with the highest overall number of clinical trials for uterine neoplasms.